Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05063344
Other study ID # NOWDx Syphilis Study
Secondary ID
Status Completed
Phase
First received
Last updated
Start date October 4, 2021
Est. completion date December 11, 2023

Study information

Verified date February 2024
Source NOWDiagnostics, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is designed to compare the performance of the NOWDx Syphilis Test to a currently marketed device. The intent is to show the rapid test device is comparable to the currently marketed device. The NOWDx Syphilis Test is intended for qualitatively detecting the presence or absence of human antibodies to syphilis in human whole blood to aid in the diagnosis of infection caused by Treponema pallidum.


Description:

The objective of this study is to establish the performance characteristics of the NOWDx Syphilis Test based on comparison to the BioRad Bioplex 2200 series Syphilis Total (IgG/IgM), Wampole Impact RPR Test Kit, and to the Serodia Treponema pallidum particle agglutination assay (TP-PA). The external clinical study along with in-house analytical studies will demonstrate the efficacy of the NOWDx Syphilis Test as an aid in the diagnosis of syphilis infection for at home testing and point of care testing sites. Participants will self test and be tested by Clinical Laboratory Improvement Amendments (CLIA) Waived operators with the NOWDx Syphilis Test at independent sites in WA, AZ, and NV. Two sample types will be tested with the NOWDx Syphilis Test for each participant: fingerstick whole blood and venous whole blood. Sera from each participant will be tested at an independent reference laboratory. The NOWDx Syphilis Test will be evaluated in diverse populations of sexually active persons who self-select for syphilis testing and expectant mothers.


Recruitment information / eligibility

Status Completed
Enrollment 1535
Est. completion date December 11, 2023
Est. primary completion date October 17, 2023
Accepts healthy volunteers
Gender All
Age group 18 Years to 64 Years
Eligibility - Sexually active persons who self-select for syphilis testing - n=840 participants; ~280 per study site - Inclusion criteria: - sexually active persons 18-64 years old - Exclusion criteria: - persons <18 years old; persons >64 years old; - persons with limited or no reading skills; - persons who previously participated in a NOWDx study - Expectant mothers - n=222 participants; ~74 per study site - Inclusion criteria: - expectant mothers =18 years old - Exclusion criteria: - persons <18 years old; - persons with limited or no reading skills; - persons who previously participated in a NOWDx study - Lay users - n=48 participants; ~16 per study site - Inclusion criteria: - persons 18-64 years old; - -½ high risk sexual behavior; ½ low risk sexual behavior - Exclusion criteria: - persons <18 years old; persons >64 years old; - persons with limited or no reading skills; - persons who previously participated in a NOWDx study

Study Design


Intervention

Device:
Diagnostic Test: NOWDx Syphilis Test
For this observational trial, the Intervention of interest is the NOWDx Syphilis Test.

Locations

Country Name City State
United States Multicare Rockwood Cheney Washington
United States AMR Las Vegas Las Vegas Nevada
United States Matrix Clinical Research Los Angeles California
United States Segal Trials North Miami Florida
United States AMR Tempe Tempe Arizona
United States People Care Institute West Orange New Jersey

Sponsors (1)

Lead Sponsor Collaborator
NOWDiagnostics, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Compare serological status to comparator method The comparator method used in this study is an algorithm comprised of results from three different commercially available syphilis assays: an FDA-cleared treponemal immunoassay, an FDA-cleared non-treponemal assay (RPR assay) and a second treponemal assay (TP-PA). through study completion, an average of 6 months
Primary Evaluate test reproducibility by lay users Test lay user reproducibility using prepared samples for % agreement with expected results. through study completion, an average of 6 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT02262390 - Syphilis Treatment of Partners Trial N/A
Active, not recruiting NCT06367621 - Retrospective Study of iStatis Syphilis Ab Test (POC)
Not yet recruiting NCT06244966 - GUM Remote Testing v4.0 N/A
Recruiting NCT05831098 - Evaluation of the Sensitivity, Specificity, and Utility of the Reveal® TP (Syphilis) Antibody POCT N/A
Completed NCT03156751 - Feasibility of Introducing an Onsite Test for Syphilis in the Package of Antenatal Care in Burkina Faso N/A
Not yet recruiting NCT05727033 - Extraordinarily Fun Training Project in Compulsory Secondary Education - Sexually Transmitted Infections N/A
Recruiting NCT06365606 - Study to Evaluate Diagnostic Sensitivity and Specificity of iStatis Syphilis Ab Test at the Point- Of-Care Sites N/A
Not yet recruiting NCT06391125 - LIMIT Trial - Lidocaine With Intramuscular Injection of Benzathine Penicillin G for Treponema Pallidum Treatment Phase 3
Not yet recruiting NCT06463314 - Multiplex Near Patient Non-HCP Study N/A
Completed NCT04455425 - Acquired Syphlis by Non Sexual Contact
Active, not recruiting NCT04050540 - Doxycycline PEP for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV PrEP Phase 4
Recruiting NCT05534633 - APPROACH 2.0: HIV, HCV and Syphilis Testing Through Pharmacies N/A
Not yet recruiting NCT05692505 - Multicenter Performance Study of QuadQuik Invitro Diagnostic Device